Janney Montgomery Scott Downgrades Pacira Pharmaceuticals (PCRX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold
October 30, 2017 2:20 AM EDTCanaccord Genuity downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $33.00 (from $44.00).
Analyst Dewey Steadman says the IMS continues to disappoint and therefore steps to the sidelines noting he expects share price pressures following guidance and efforts by... More
